London, UK - 08 November 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Vortex Biosciences previewed the VTX-1, a fully automated system for the efficient enrichment of intact circulating tumor cells (CTCs) from whole blood, at the ...
Vortex Biosciences Announces Publications Supportive of its Circulating Tumour Cell Technology London, UK - March 31st 2017 - NetScientific plc (AIM:NSCI), the transatlantic healthcare IP ...
Vortex is a leader in liquid biopsy of circulating tumor cells (CTCs).The Vortex Biosciences VTX-1 instrument is fully automated, providing highly purified, intact CTCs in approximately 1 hour.These ...
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...
The Cancer Hub aims to create a world-leading ecosystem for cancer research The Cancer Hub aims to create a world-leading ecosystem for cancer research Vortex Biosciences has expanded its liquid ...
Today EMV Capital announces the acquisition of a controlling stake in Bay Area-based Vortex Biosciences, and a further investment package to accelerate the company’s development. Robert Englert, CEO ...
The old ways of capturing tumor cells left much to be desired. For cancer centers, the best option was often a tissue biopsy, however painful, however risky. Alternatively, a cancer center might try ...
Vortex Biosciences previewed the VTX-1, a fully automated system for the efficient enrichment of intact circulating tumor cells (CTCs) from whole blood, at the American Association for Cancer Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results